Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease (TELEX)
Patients with lower extremity peripheral artery disease (PAD) have greater walking impairment and increased mobility loss, compared to people without PAD. Yet few effective therapies have been identified to help patients with PAD improve their walking impairment or prevent mobility loss. Based on promising preliminary evidence, we hypothesize that telmisartan, an oral angiotensin receptor blocker, will improve walking ability and prevent functional decline in people with PAD. We further hypothesize that telmisartan combined with supervised exercise will have substantially greater benefit than either individual therapy alone.
Site Principal Investigator: Lydia A Bazzano, MD, PhD